Pharmacy Industry Newsletter
Get weekly insights on pharmacy billing, NDC updates, and revenue optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime.
Regenxbio's Duchenne gene therapy heads to FDA
PLUS: FDA leadership search narrows, BeOne wins lymphoma approval, and Lilly-Novo obesity battle heats up
Trump to Fire FDA Chief Makary
PLUS: Roche acquires AI pathology firm for $750M, Lilly invests $4.5B in manufacturing, Supreme Court extends mifepristone access
Sanofi pulls drug from FDA program after interference
PLUS: Novo's Wegovy pill hits $355M debut, Angelini buys Catalyst for $4.1B, and FDA blocks vaccine safety studies
Supreme Court restores mifepristone access
PLUS: FDA approves first PROTAC cancer drug, UCB acquires bispecifics maker for $2.2B, hantavirus outbreak on cruise ship
Purdue Pharma to Dissolve After Criminal Sentence
PLUS: Trump names new surgeon general nominee, AI outperforms doctors in diagnostics, and $2.6B in pharma deals
Sun Pharma's $11.75B Organon Buyout Tops 2026 Deals
PLUS: Intellia's CRISPR therapy succeeds in pivotal trial, Lilly acquires two innovation-focused companies, and FDA fast-tracks psychedelic treatments
FDA Approves Regeneron Gene Therapy for Hearing Loss
PLUS: Trump's drug pricing deals, Merck's $1B Google AI partnership, and AbbVie's $1.4B North Carolina campus
Trump orders FDA to fast-track psychedelics review
PLUS: Lilly acquires cell therapy firm for $3.25B, CAR-T shows promise in preventing myeloma, and Revolution Medicines' KRAS data
Kailera nets $625M in massive obesity drug IPO
PLUS: Lilly's oral obesity pill clears heart safety hurdle, Roche plans new Elevidys trial, Novartis CEO joins AI board
Merck acquires Terns for $6.7B in oncology bet
PLUS: FDA approves rare disease therapies for Hunter syndrome and ovarian cancer, medical schools drop equity requirements
Pfizer's Lyme vaccine moves forward despite mixed data
PLUS: FDA expands Rhythm's obesity drug, Parkinson's med safety updates, and 22,000+ pharma job cuts in 2025
Lilly's triple-G obesity drug hits Phase 3 milestone
PLUS: Novo's high-dose Wegovy wins FDA approval, J&J's oral psoriasis pill clears regulatory hurdles, and NIH funding crisis deepens
Judge blocks RFK Jr. vaccine policy overhaul
PLUS: Oral GLP-1 pill shows promising weight loss results, GSK expands RSV vaccine, and White House pushes most-favored nation drug pricing
FDA Launches Unified Safety Surveillance System
PLUS: Lilly warns of impurities in GLP-1 knockoffs, commits $3B to China manufacturing, and MedPAC calls out Medicare Advantage overpayments
Vinay Prasad Exits FDA as Biotech Stocks Rally
PLUS: BioNTech founders launch new mRNA venture, Novo strikes Hims deal, and Vertex kidney drug succeeds in trial
Lilly bypasses insurers with employer GLP-1 program
PLUS: Moderna settles COVID vaccine patent fight for $2.25B, FDA cracks down on compounded weight loss drugs
CMS Halts Elevance Medicare Advantage Enrollment
PLUS: FDA approves Ascendis dwarfism drug, UniQure gene therapy setback, AI chatbot gets breakthrough status
Lilly's GLP-1 pill beats Novo's Rybelsus in Phase 3
PLUS: FDA faces Senate scrutiny on rare disease reviews, Sarepta CEO announces retirement, and Generate raises $400M in IPO
Novo's Obesity Drug Fails Against Lilly's Zepbound
PLUS: Gilead's $7.8B Arcellx buy, FDA's gene therapy roadmap, and Merck's oncology split
DOJ sues OhioHealth over anticompetitive contracts
PLUS: Grail's cancer test misses study goal, Supreme Court strikes down tariffs, and Vertex's CRISPR therapy rebounds
FDA reverses course on Moderna's flu vaccine review
PLUS: New standard for drug approvals, psilocybin heads to FDA, and Grail's cancer test setback
Digital Health Integration Transforms Modern Pharmacy Practice
PLUS: AI clinical tools gain traction, remote patient monitoring expands, and pharmacy apps reshape patient engagement
Harm reduction programs gain ADA legal protections
PLUS: AstraZeneca targets 25+ blockbusters by 2030, fentanyl smoking linked to fewer overdoses, Hims faces regulatory scrutiny
Biosimilar Adoption Surges as Patents Expire on Major Biologics
PLUS: New adalimumab biosimilar enters market, oncology biosimilar pipeline expands, and payer formulary shifts accelerate
New CMS Rules Reshape 340B Program Oversight for 2026
PLUS: Hospital outpatient drug spending surges, insulin pricing update, and pharmacy quality measure changes
Independent Pharmacies Fight Back Against PBM Practices
PLUS: FTC releases damning PBM report, state attorney general actions, and pharmacy coalition gains momentum
FDA Accelerates Generic Drug Approvals in Push for Lower Prices
PLUS: New compounding regulations proposed, telepharmacy expansion, and specialty drug pipeline update
CVS Health Restructuring Plan Shakes Up Retail Pharmacy Landscape
PLUS: Walgreens explores going private, generic drug pricing trends, and pharmacy technician shortage deepens
What's Ahead for Pharmacy in 2026: Trends and Predictions
PLUS: New year drug launches, reimbursement outlook, and technology trends to watch
Pharmacy Industry Year in Review: The Biggest Stories of 2025
PLUS: Top drug launches, regulatory milestones, and what shaped pharmacy practice this year
Medicare Part D Changes Bring Relief for Seniors' Drug Costs in 2026
PLUS: Pharmacy deserts expand, biosimilar Humira gains market share, and new antibiotic wins FDA approval
Eli Lilly's Weight-Loss Drug Expansion Signals New Era in Obesity Treatment
PLUS: Novo Nordisk supply chain update, pharmacy benefit reform advances, and CVS earnings surprise